media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

World Health Expo Lagos

Organiser：Informa Time： June 2nd – 4th, 2026 Address：10 Dr Nurudeen Olowopopo Way, Agidingbi, Ikeja Exhibition hall：Lagos International Conference and Exhibition Center Product range: Medical Devices: Blood pressure monitors, microscopes, audiometers, X-ray machines, CT scanners, magnetic resonance imaging (MRI) machines, B-ultrasound machines, biochemical analyzers, electrocardiographs, laser therapy machines, ventilators, blood bank equipment, medical video and photography equipment, medical aesthetic equipment, orthopedic equipment, etc. Medical Consumables: Surgical, emergency room, and consultation room instruments; surgical gowns, shoes, and gloves; various medical surgical knives, forceps, scissors; disposable items; test tubes; band-aids; masks; bandages; stethoscopes; toolkits; work uniforms; syringes, etc. Rehabilitation Products: Orthotic devices, walkers, massagers, health beds, medical beds, medical bathtubs, crutches, wheelchairs, health-care apparel, fitness equipment Health Care Products: Home health care products, small-sized home diagnostic, monitoring, and treatment instruments; rehabilitation and physiotherapy instruments and supplies; oral and dental health care products and related items; health care devices, etc. Laboratory Equipment: Laboratory utensils, various reagents, test papers, test ...
- Source: drugdu
- 49
- December 11, 2025
How to Use B2B Platforms to Expand Global Sales Channels

As global pharmaceutical markets place increasing demands on the variety, quality and compliance of excipients, more and more excipient manufacturers are looking to move beyond their domestic markets and enter the international arena. However, the reality often looks like this: Overseas customers simply cannot find you Building your own international sales team is costly and time-consuming Lack of experience in registration and professional presentation makes it hard to build trust This article focuses on how excipient manufacturers can leverage B2B platforms to expand globally, and aims to provide small and medium-sized companies with a practical, repeatable and cost-controllable approach. I. Typical Challenges for Excipient Manufacturers Going Global 1. Single-channel dependence: heavily reliant on offline and personal networks Most companies still rely on a traditional mix of: “Domestic pharma exhibitions + trading companies + personal connections” This model is low in efficiency and makes it difficult to build a scalable and ...
- Source: drugdu
- 51
- December 10, 2025
【EXPERT Q&A】What certifications are required for the export of pharmaceutical products?

Drugdu.com expert’s response: Pharmaceutical products need to obtain four major types of certifications based on the regulatory requirements of the target markets for export: quality management system certification, regional market access certification, production specification certification, and special product-specific certifications, as detailed below: I. Quality Management System Certification (Internationally Recognized) ISO 13485 Certification Scope of Application: Applicable to all medical device companies exporting products. Certification Content: An international standard for the quality management system of medical devices, covering the entire process of design, production, installation, and service. Function: Demonstrates that the enterprise has the capability to consistently produce products that comply with international standards, serving as the “basic threshold” for entering most markets. Regional Market Access Certification (Select Based on Target Market) EU Market CE Certification: Applicable Products: All medical devices (Class I low-risk products require a Declaration of Conformity, while Classes IIa/IIb/III require a CE certificate). Regulatory Basis: Must comply ...
- Source: drugdu
- 46
- December 10, 2025
WHO releases guidelines for the use of new weight-loss drugs

In response to the growing global challenge of obesity, the World Health Organization recently released its first global guideline　　on the use of glucagon-like peptide-1 (GLP-1) drugs for the treatment of obesity.Three drugs used to treat obesity in adults: liraglutide, smegglutide, and telpoglutide. The World Health Organization (WHO) defines obesity as an adult body mass index (BMI) of 30 or higher. According to WHO data, obesity is a chronic, relapsing disease, affecting more than one billion people globally. Obesity-related deaths reached 3.7 million in 2024. Without decisive action, the number of obese individuals is projected to double by 2030. WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated, “Obesity is a major global health challenge, and the WHO is committed to supporting countries and people worldwide in addressing it effectively and equitably. The new guidelines acknowledge that obesity is a chronic disease that can be treated with comprehensive, lifelong care. While medication alone ...
- Source: drugdu
- 60
- December 9, 2025
Grand Pharmaceutical’s Class 1 innovative traditional Chinese medicine drug GPN01360 has reached its clinical endpoint in the Phase II clinical trial in China

On December 8, Grand Pharmaceutical (00512) issued an announcement stating that the Group’s traditional Chinese medicine…Class 1 innovative drugsThe Phase II clinical trial of GPN01360 in China successfully met its clinical endpoint. This study enrolled 148 patients with depression, who received oral administration for 8 weeks. The primary assessment was the efficacy and safety of GPN01360 compared to placebo in treating depression. Results showed that the primary efficacy endpoint, the change from baseline on the Hamilton Depression Rating Scale (HAMD-17), was significantly different from placebo (P=0.0006<0.05). Secondary efficacy endpoints, such as the Montgomery-Asperger’s Depression Rating Scale (MADRS), also showed significant differences (P<0.05). Furthermore, GPN01360 demonstrated good safety and tolerability, with no significant toxic side effects observed. GPN01360 is a Class 1.1 innovative traditional Chinese medicine 　　for the treatment of depression . Its main ingredients include 12 herbs such as Bupleurum, Curcuma longa, and Citrus medica , which have the effects ...
- Source: drugdu
- 58
- December 9, 2025
Incyte Pharma Drug Shows Positive Effect in Treatment of a Certain Type of Blood Cancer

Incyte Pharma states new clinical data shows its monoclonal antibody drug INCA033989 can rapidly and significantly reduce spleen volume, alleviate associated symptoms, and improve anemia in patients with myelofibrosis who have a specific genetic mutation. The preliminary research results come from treating patients with CALR mutation (mutCALR) myelofibrosis with the drug as monotherapy and in combination with ruxolitinib. The drug demonstrated good safety, with no dose-limiting toxicities reported. Incyte Pharma plans to initiate a registration program for myelofibrosis treatment in 2026. https://finance.eastmoney.com/a/202512073584646874.html
- Source: drugdu
- 49
- December 9, 2025
Ophthalmic preparation GB10 injection receives clinical trial approval notice

Securities Daily Online News On the evening of December 8th, Sinovac Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Shenzhen Sinovac Pharmaceutical Co., Ltd., recently received a “Notice of Drug Clinical Trial Approval” from the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Sinovac to carry out clinical trials for the “GB10 Injection”. https://finance.eastmoney.com/a/202512083585556010.html
- Source: drugdu
- 50
- December 9, 2025
Huadong Medicine enters commercialization partnership with Sinorda Pharma

China Securities Journal, China Securities Network (Reporter Fu Suying) – On December 7, Huadong Medicine’s wholly-owned subsidiary Huadong Medicine (Hangzhou) Co., Ltd. announced that it has entered into an exclusive commercialization partnership for mainland China with Guizhou Sinorda Biotech Co., Ltd. and its wholly-owned subsidiaries Shanghai Sinorda Pharmaceutical Technology Co., Ltd. and Jiangsu Taris Sinorda Biopharmaceutical Co., Ltd. (collectively referred to as “Sinorda Pharma”). The partnership covers Sinorda’s product Linaprazan Glutarate Capsules and other dosage forms. Linaprazan is a next-generation potassium-competitive acid blocker (P-CAB) drug co-developed by Sinorda Pharma and Cinclus Pharma for the treatment of digestive system diseases. Leveraging Huadong Medicine’s strong commercialization platform, Linaprazan is expected to achieve rapid market uptake and will further enhance Huadong Medicine’s product portfolio in the digestive disease field. On December 7, the National Healthcare Security Administration disclosed that Linaprazan, indicated for gastroesophageal reflux disease, and the PARP inhibitor Senaparib (Paisuning®) have been ...
- Source: drugdu
- 47
- December 9, 2025
Changchun High & New Tech’s Two Drugs from Controlled Subsidiaries Added to National Reimbursement Drug List

Changchun High & New Tech (000661) announced on the evening of December 8 that, according to the National Drug Reimbursement List for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025) (Medical Insurance Notice [2025] No. 33, hereinafter referred to as the “National Reimbursement Drug List”) jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from the company’s controlling subsidiary, Changchun GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as “GeneScience Pharma”), have been newly included in the National Reimbursement Drug List. These are Jinsaizeng (currently the generic name is “Jinpei Growth Hormone Injection”), which was independently developed by GeneScience Pharma, and Meishiya (generic name: “Megestrol Acetate Oral Suspension”), which was introduced through cooperation. It is reported that Jinsaizeng is the world’s first long-acting growth hormone approved for market by GeneScience Pharma in January 2014. Its currently approved indications include: ...
- Source: drugdu
- 46
- December 9, 2025
Chinese-made ADCs stun the field once again

The ESMO-Asia (European Society for Medical Oncology Asian Congress) will be held in Singapore from December 5-7, 2025. At ESMO-Asia, Baili Tianheng presented clinical data for the first time on its next-generation HER2 ADC drug T-Bren (BL-M07D1) for the treatment of HER2-mutant non-small cell lung cancer. The study results show that T-Bren has excellent efficacy and outstanding safety in treating HER2-mutant lung cancer, and is expected to become the best-in-class HER2 ADC. Patients with HER2-mutant lung cancer have long faced treatment challenges. HER2 mutations account for approximately 2%-4% of non-small cell lung cancer patients, and are more common in non-smokers, women, and patients with lung adenocarcinoma. However, the objective response rate of chemotherapy for this disease is only 30%, and the median progression-free survival is about 6 months. Immunotherapy monotherapy and combination therapy have limited efficacy, with first-line combination therapy resulting in a PFS of only 5-10 months. Therefore, HER2 ...
- Source: drugdu
- 44
- December 9, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.